Evofem Biosciences Inc logo

Evofem Biosciences Inc

$ 0.08 +0.0043 (+5.77%) 10:09 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 6.74M
Enterprise V:
$ 112.22M
Volume:
986.15K
Avg Vol (2M):
2.36M
Also Trade In:
Volume:
986.15K
Market Cap $:
6.74M
PE Ratio:
At Loss
Avg Vol (2-Month):
2.36M
Enterprise Value $:
112.22M
PB Ratio:
0

Business Description

Description
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The company is also evaluating its investigational drug candidate EVO100 vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.16
Equity-to-Asset -4.04
Debt-to-Equity -0.58
Debt-to-EBITDA -0.95
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -48.91
Distress
Grey
Safe
Beneish M-Score -3.15
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 65.23
9-Day RSI 53.15
14-Day RSI 44.84
6-1 Month Momentum % -77.04
12-1 Month Momentum % -98.68

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.16
Quick Ratio 0.14
Cash Ratio 0.07
Days Inventory 569.73
Days Sales Outstanding 118.68
Days Payable 782.29

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -84.5

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 67.49
Operating Margin % -861.66
Net Margin % -1821.05
ROA % -462.1
ROIC % -97.53
ROC (Joel Greenblatt) % -675.72

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 0.08
EV-to-EBIT -0.84
EV-to-EBITDA -0.85
EV-to-Revenue 7.25
EV-to-Forward-Revenue 3.22
EV-to-FCF -1.04
Earnings Yield (Greenblatt) % -119.05